What is HighRes Biosolutions?
HighRes Biosolutions operates at the intersection of robotics and molecular biology, providing modular automation platforms that redefine laboratory efficiency. Their flagship software, Cellario, serves as the central nervous system for complex research environments, enabling seamless integration of precision liquid handling and automated workflows. By focusing on scalability and reproducibility, the company addresses the primary bottlenecks in genomics and synthetic biology. Their market position is defined by a commitment to transforming manual, error-prone processes into intelligent, data-driven workflows that empower life science organizations to achieve greater throughput and scientific accuracy.
How much funding has HighRes Biosolutions raised?
HighRes Biosolutions has raised a total of $2.5M across 1 funding round:
Private Equity
$2.5M
Private Equity (2015): $2.5M, investors not publicly disclosed
Key Investors in HighRes Biosolutions
Undisclosed Institutional Investor
A private equity firm specializing in long-term capital appreciation for high-growth technology and industrial automation companies.
What's next for HighRes Biosolutions?
With this major strategic investment, HighRes Biosolutions is well-positioned to expand its footprint in the global enterprise biotech market. The company is expected to leverage this capital to enhance its Cellario software capabilities, potentially integrating advanced machine learning modules to further optimize experimental design and data analysis. As the industry shifts toward fully autonomous laboratories, HighRes is likely to prioritize the development of next-generation modular hardware that offers greater flexibility for diverse research applications. Future growth will likely center on deepening partnerships with pharmaceutical giants and academic research centers, ensuring that their automation technologies remain the standard for high-stakes drug discovery and clinical development programs.
See full HighRes Biosolutions company page
